<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255996</url>
  </required_header>
  <id_info>
    <org_study_id>A5951109</org_study_id>
    <nct_id>NCT00255996</nct_id>
  </id_info>
  <brief_title>Evaluation Of Linezolid Pk Profile In Burns Patients</brief_title>
  <official_title>An Open Label Parallel Group Study To Investigate The Pharmacokinetics Of Intravenous Linezolid, An Oxazolidinone, Administered To Healthy Volunteers And Patients With Major Thermal Injuries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      Evaluation of linezolid pk profile in burns patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess and compare pharmacokinetic parameters of a single dose 1-hour intravenous linezolid (Zyvox) at 600 mg in patients with major thermal injuries (&gt;40% body area) and in healthy volunteers</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess and compare tolerability and safety of a single dose of 600mg IV linezolid administered in patients with major thermal injuries (&gt;40% body area) and in healthy volunteers.</measure>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Burns</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linezolid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with a Body Mass Index (BMI) &lt; 30 kg/m&amp;#178;. For patient with major thermal
             injuries, the weight will be collected before the burn ;

          -  Patients with major thermal injuries &gt;40% body area including 3rd degree burns with
             full thickness burns ;

          -  Patients hospitalized for at least 10 days since their thermal injury occurred ;

        Exclusion Criteria:

          -  Contra-indications to use linezolid as mentioned in the SmPC (Summarized Product
             Characteristics) : hypersensitivity to linezolid use or to any of its components,
             non-controlled hypertension, phaeochromocytoma, carcinoid syndrome, hyperthyroidism,
             bipolar disorders, schizoaffective disorders, acute confused state of mind, pregnancy,
             and breastfeeding ;

          -  Drugs metabolised by monoamine oxydase (MAO) should be evaluated for potential
             drug-to-drug interaction;

          -  Subject treated by: selective serotonin reuptake inhibitors (Prozac&amp;#174;,
             Effexor&amp;#174;, Ixel&amp;#174; &amp;#133;), tricyclic antidepressant (Anafranil&amp;#174;,
             Sinequan&amp;#174;, Surmontil&amp;#174;, Tofranil&amp;#174;), 5HT1 receptor agonists (triptan)
             direct or indirect sympathomimetic (including adrenergic bronchodilator,
             pseudoephedrine and phenylpropylamine), vasopressor (adrenaline and noradrenaline),
             dopaminergic drugs (dopamine, dobutamine), phenetidine or buspirone should be
             evaluated for potential drug-to-drug interaction;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5951109&amp;StudyName=Evaluation+Of+Linezolid+Pk+Profil+In+Burns+Patients</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2005</study_first_submitted>
  <study_first_submitted_qc>November 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>July 13, 2009</last_update_submitted>
  <last_update_submitted_qc>July 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

